5443502026-04-012026-06-305443502026-06-305443502026-04-012026-06-30in-capmkt:OtherExpenses1Member5443502026-04-012026-06-30in-capmkt:OtherExpenses2Member5443502026-04-012026-06-30in-capmkt:OtherExpenses3Member5443502026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15443502026-06-30Statement15443502026-04-012026-06-30Statement15443502026-06-30StatementDynamic1I1Statement15443502026-06-30StatementDynamic1I2Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares544350AGARWALEYENOTLISTEDINE943P01029DR. AGARWAL'S HEALTH CARE LIMITEDMain BoardEquity2026-04-012027-03-312026-08-042026-07-28INRCroresQuarterlyFirst quarterSingle segmentEye care related sales and services2026-08-0411:50:002026-08-0413:45:00Not applicabletrue1falseThe Company has not defaulted on any loans availed.2026-04-012026-06-30UnauditedStandalone38262000003420000038604000000412500000-60700000710700000189600000575300000180800000036354000002250000000225000000109200000-509000005830000001667000000000166700000-730000015940000031700000010.530.52000.530.52Please refer to our PDF disclosure of Outcome of Board Meeting dated August 04, 2026 filed in this regard for the notes on Unaudited (Consolidated & Standalone) Financial Results of the Company for the quarter ended June 30, 2026.Other Expenses669400000Consumption of Surgical lens including other consumables481600000Consultancy Charges for Doctors (Net)657000000Remeasurement gain / (loss) on defined benefit obligation-9700000-9700000-24000000-7300000Public Issues2025-01-3130000000002026-06-30trueICRA LimitedfalseNANoneNoneThanikainathan ArumugamCompany Secretary and Compliance OfficerChennai2026-08-04Issue related expenses-2753000000126500000148800000As already disclosed vide our letter dated May 21, 2026, the Company had successfully completed the Initial Public Offering with lower-than anticipated statutory, legal, and marketing costs due to effective cost-management and competitive negotiations. Allocating the unutilized / surplus money from ‘Issue related expenses’ toward 'General Corporate Purposes and unidentified inorganic acquisition' provides the Company with a robust liquidity buffer supporting the scaling of its existing operations and meeting unexpected contingencies. <br /> <br /> The aforesaid reallocation shall remain in strict compliance with Regulation 7 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, wherein the amount to be utilised for general corporate purposes and towards unidentified inorganic acquisition shall not, in aggregate, exceed 35% of the Gross Proceeds, out of which the amounts to be utilised towards either (i) general corporate purposes, or (ii) unidentified inorganic acquisitions shall not exceed 25% of the Gross Proceeds. General corporate purposes and unidentified inorganic acquisition-774700000923500000746600000148800000As already disclosed vide our letter dated May 21, 2026, the Company had successfully completed the Initial Public Offering with lower-than anticipated statutory, legal, and marketing costs due to effective cost-management and competitive negotiations. Allocating the unutilized / surplus money from ‘Issue related expenses’ toward 'General Corporate Purposes and unidentified inorganic acquisition' provides the Company with a robust liquidity buffer supporting the scaling of its existing operations and meeting unexpected contingencies. <br /> <br /> The aforesaid reallocation shall remain in strict compliance with Regulation 7 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, wherein the amount to be utilised for general corporate purposes and towards unidentified inorganic acquisition shall not, in aggregate, exceed 35% of the Gross Proceeds, out of which the amounts to be utilised towards either (i) general corporate purposes, or (ii) unidentified inorganic acquisitions shall not exceed 25% of the Gross Proceeds.